AR008895A1 - Composicion granulada util como vehiculo farmaceutico para la preparacion de una composicion suspendible en agua, procedimiento para su preparacion,producto granulado de suspension y procedimiento para prepararlo, y composicion farmaceutica suspendible en agua. - Google Patents

Composicion granulada util como vehiculo farmaceutico para la preparacion de una composicion suspendible en agua, procedimiento para su preparacion,producto granulado de suspension y procedimiento para prepararlo, y composicion farmaceutica suspendible en agua.

Info

Publication number
AR008895A1
AR008895A1 ARP970104897A ARP970104897A AR008895A1 AR 008895 A1 AR008895 A1 AR 008895A1 AR P970104897 A ARP970104897 A AR P970104897A AR P970104897 A ARP970104897 A AR P970104897A AR 008895 A1 AR008895 A1 AR 008895A1
Authority
AR
Argentina
Prior art keywords
water
preparation
composition
granulated
pharmaceutical
Prior art date
Application number
ARP970104897A
Other languages
English (en)
Original Assignee
Eurand Internat S P A Italan Joint Stock C O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurand Internat S P A Italan Joint Stock C O filed Critical Eurand Internat S P A Italan Joint Stock C O
Publication of AR008895A1 publication Critical patent/AR008895A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composicion granular util como vehículo farmacéutico que puede utilizarse para la preparacion de composiciones farmacéuticas que puedansuspenderserápidamente en agua o en un medio acuoso, incluyendo la saliva. Las composiciones pueden utilizarse mediante su adiccion a un vaso de agua conagitacion o introducirse directamente en la boca. La composicion granular comprende uno o mas agentes espesantes y uno o más agentes desintegrantes ypuede prepararse mediante un procedimientoque comprende someter una mezcla de un agente espesante y un agente desintegrante a granulacion en humedo con unmedio acuoso como agente humectante o a granulacion en seco para preparar un nuevo producto granulado y preparar la composicion farmacéutica a prtir delproducto granulado y del fármaco. Antes de mezclarse con el fármaco, el producto granulado puede mezclarse con un exipiente inerte soluble en agua, quepuede ser azucar. Asimismo, se provee el procedimiento para la prepararcion de dicha composicion, un producto granulado de suspension y un procedimiento parasu preparacion, y una composicion farmacéutica suspendible en agua. Solo a modo ilustrativo y ejemplificativfo se mencionan algunos agentes espesantes, comogoma de xantano, carragenina, alginatos, agar-agar, goma de tragacanto, goma guar, goma de carnauba, goma karaya y almidon de maíz modificado; algunosagentes desintegrantes como ácido algínico, sal cálcica de carboximetilcelulosa , dioxido de silisio coloidal, silicato de aluminio y magnesio, almidon yderivados de almidon y alginato sodico, glicolato de almidon sodico, polivinilpirrolidona CL(reticulada) y carboximetilcelulosa sodica CL(reticulada) y algunos compuestos activos como acetilcisteína, acido acetisalicílico, amitriptilina, nicardipina, bromazepan, fluoxetina,
ARP970104897A 1996-10-23 1997-10-23 Composicion granulada util como vehiculo farmaceutico para la preparacion de una composicion suspendible en agua, procedimiento para su preparacion,producto granulado de suspension y procedimiento para prepararlo, y composicion farmaceutica suspendible en agua. AR008895A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9622090A GB2318511A (en) 1996-10-23 1996-10-23 Process for the preparation of a pharmaceutical composition for rapid suspension in water

Publications (1)

Publication Number Publication Date
AR008895A1 true AR008895A1 (es) 2000-02-23

Family

ID=10801863

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970104897A AR008895A1 (es) 1996-10-23 1997-10-23 Composicion granulada util como vehiculo farmaceutico para la preparacion de una composicion suspendible en agua, procedimiento para su preparacion,producto granulado de suspension y procedimiento para prepararlo, y composicion farmaceutica suspendible en agua.

Country Status (9)

Country Link
US (1) US6261602B1 (es)
EP (1) EP0936901A1 (es)
JP (1) JP4129995B2 (es)
AR (1) AR008895A1 (es)
AU (1) AU725958B2 (es)
CA (1) CA2268626C (es)
GB (1) GB2318511A (es)
WO (1) WO1998017250A1 (es)
ZA (1) ZA979425B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184220B1 (en) 1998-03-27 2001-02-06 Boehringer Ingelheim Pharma Kg Oral suspension of pharmaceutical substance
EP0945131A1 (de) * 1998-03-27 1999-09-29 Boehringer Ingelheim Pharma KG Perorale Wirkstoff-Suspension
BR0009557A (pt) 1999-04-06 2002-05-28 Ethypharm Lab Prod Ethiques Suspensão farmacêutica para beber de ibuprofeno
US6632429B1 (en) * 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
BR0109544A (pt) * 2000-03-28 2003-06-10 Biochemie Gmbh Partìculas granuladas com sabor ocultado
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
US20070053895A1 (en) * 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US6596708B1 (en) 2001-09-07 2003-07-22 Advanced Medical Instruments Composition for the treatment and prevention of endothelial dysfunction
GB0123400D0 (en) * 2001-09-28 2001-11-21 Novartis Ag Organic compounds
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
MXPA04009979A (es) * 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxicilina.
US8100844B2 (en) * 2002-04-25 2012-01-24 Ultraflex Systems, Inc. Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint
US20040258716A1 (en) * 2002-06-17 2004-12-23 Shen Gao Ibuprofen suspension
BG738Y1 (bg) * 2002-07-02 2005-05-31 Balkanfarma Razgrad Ad Лекарствена форма
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US20040170686A1 (en) * 2003-01-31 2004-09-02 Fredrickson Jennifer K. Suspension vehicle for coated drug particles
US20040191326A1 (en) * 2003-03-31 2004-09-30 Reo Joseph P. Taste-masking vehicle for coated oxazolidinone particles
US20070053981A1 (en) * 2003-07-11 2007-03-08 Eva Blychert Solid composition comprising a proton pump inhibitor
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
US20060134210A1 (en) * 2004-12-22 2006-06-22 Astrazeneca Ab Solid dosage form comprising proton pump inhibitor and suspension made thereof
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
HUE029444T2 (en) 2008-01-04 2017-02-28 Schabar Res Ass Llc A composition containing an analgesic and an antihistamine
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) * 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
US11016104B2 (en) * 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US9173916B2 (en) 2008-07-31 2015-11-03 Shaklee Corporation Method of preparing a muscadine pomace extract
WO2010014870A2 (en) 2008-07-31 2010-02-04 Shaklee Corporation Muscadine compositions with improved anti-oxidant activity
US9132162B2 (en) 2008-07-31 2015-09-15 Shaklee Corporation Muscadine compositions with anti-oxidant activity
US8512771B2 (en) 2008-07-31 2013-08-20 Shaklee Corporation Method of preparing a muscadine pomace extract
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) * 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
EP2373693A4 (en) 2009-01-06 2012-04-25 Curelon Llc COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF ORAL INFECTIONS BY E. COLI
DK3064217T3 (en) 2009-01-06 2018-05-28 Galenagen Llc COMPOSITIONS COMPREHENSIVE PROTEASE, AMYLASE AND LIPASE FOR USE IN TREATMENT OF STAPHYLOCOCCUS AUREUS INFECTIONS
JP2012072061A (ja) * 2009-01-29 2012-04-12 Eisai R & D Management Co Ltd 新規組成物
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
EP2440210A4 (en) 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
JP5559339B2 (ja) 2009-10-12 2014-07-23 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング メロキシカムを含む組成物のための容器
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2519229A2 (en) 2009-12-29 2012-11-07 Novartis AG New pharmaceutical dosage form for the treatment of gastric acid-related disorders
BR112012022073A2 (pt) 2010-03-03 2017-10-31 Boehringer Ingelheim Vetmedica Gmbh uso de meloxicam para o tratamento de longa duração de distúrbios musculoesqueletais em gatos.
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
ES2726978T3 (es) 2011-04-21 2019-10-11 Curemark Llc Compuestos para el tratamiento de trastornos neuropsiquiátricos
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
EP3082770A1 (en) 2013-12-20 2016-10-26 Disphar International B.V. Dry enema product
WO2016154313A1 (en) * 2015-03-24 2016-09-29 Zywie, Llc High drug loading liquid oral pharmaceutical compositions
WO2018017608A1 (en) 2016-07-19 2018-01-25 Shaklee Corporation Muscadine topical composition with low content of condensed tannin molecules
US11331307B2 (en) 2020-07-15 2022-05-17 Schabar Research Associates, Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1183574B (it) * 1985-05-08 1987-10-22 Eurand Spa Metodo per ottenere una sospensione estemporanea omogenea di microcapsule
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
IT1246350B (it) * 1990-07-11 1994-11-17 Eurand Int Metodo per ottenere una rapida sospensione in acqua di farmaci insolubili
IT1250421B (it) * 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.

Also Published As

Publication number Publication date
ZA979425B (en) 1999-04-21
WO1998017250A1 (en) 1998-04-30
AU5188798A (en) 1998-05-15
JP4129995B2 (ja) 2008-08-06
JP2000508342A (ja) 2000-07-04
US6261602B1 (en) 2001-07-17
EP0936901A1 (en) 1999-08-25
AU725958B2 (en) 2000-10-26
CA2268626C (en) 2007-03-06
GB2318511A (en) 1998-04-29
CA2268626A1 (en) 1998-04-30
GB9622090D0 (en) 1996-12-18

Similar Documents

Publication Publication Date Title
AR008895A1 (es) Composicion granulada util como vehiculo farmaceutico para la preparacion de una composicion suspendible en agua, procedimiento para su preparacion,producto granulado de suspension y procedimiento para prepararlo, y composicion farmaceutica suspendible en agua.
ES2234511T3 (es) Aditivacion de nanofibrillas de celulosa esencialmente amorfas con celulosa carboxilada con alto grado de sustitucion.
Vallyathan et al. Reactive oxygen species: their relation to pneumoconiosis and carcinogenesis.
JP3180350B2 (ja) β―ラクタム系抗生物質含有錠剤およびその製造法
EP0934054B1 (en) Dispersible water-soluble or water-swellable polymers
US6258342B1 (en) Process for making toothpaste using agglomerated dispersible polymers
TNSN97114A1 (fr) Granule pour la preparation des compositions a desintegration et dissolution rapides comprenant une teneur elevee d'un principe actif
CA2439570A1 (en) In-situ gel formation of pectins
AU2010252929B2 (en) Dry powder fibrin sealant
KR920702215A (ko) 수중에서 신속하게 현탁제를 형성하는 약제학적 조성물
JPS62123112A (ja) 軟膏基剤
CN105434397A (zh) 一种植物性软胶囊胶皮组合物及其制备方法
CN104800189A (zh) 一种淀粉植物空心胶囊
EA018071B1 (ru) Изомальтсодержащая смесь для получения быстро разрушающихся таблеток, способ ее получения и таблетка
EP0305365B1 (en) Periodontal composition and method
CA2388325C (en) Ciclesonide-containing aqueous pharmaceutical composition
NO991195L (no) Fremstilling av doseringsenheter ved bruk av lavskjaer-granulering
CN110313618A (zh) 一种维生素d2微胶囊的制备方法
YU27399A (sh) Postupak za dobijanje natrijum-perkarbonata
WO2010136818A2 (en) Dry powder fibrin sealant
PT1232746E (pt) Composição farmacêutica que compreende goma xantana
AR001349A1 (es) Nueva composición farmacéutica que contiene trimebutina y proceso para su preparación.
FI885506A (fi) Farmaceutisk komposition och foerfarande foer framstaellning daerav.
JP2005298454A (ja) 粉末状入浴剤組成物
UA94275C2 (ru) Фармацевтическая композиция, которая содержит по крайней мере один активный наркотический или психотропный компонент, назначенный способ введения которых в организм тяжело поддается изменению

Legal Events

Date Code Title Description
FA Abandonment or withdrawal